Prof Philip Moreau speaks to ecancer about the key data presented at the Controversies in Multiple Myeloma 2022 meeting (COMy), held May 12-15th in Paris.
He starts off by updating us on the latest progression-free survival (PFS) and depth of response data in the phase 3 IKEMA trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) versus carfilzomib and dexamethasone (Kd) in relapsed multiple myeloma. This found that the median PFS with Isa-Kd was 35.7 months (95% CI, 25.8-44.0) vs 19.2 months (95% CI, 15.8-25.1) with Kd alone, converting to a 42% reduction in the risk of disease progression or death.
He then discusses a meta-analysis of ciltcabtagene autoleucel (CILTA-CEL) versus physician’s choice of treatment (PCT) for patients with relapsed or refractory multiple myeloma. Prof Moreau also touches on updates from cohort B of the CARTITUDE-2 study.
He talks about the efficacy and safety of ciltacabtagene autoleucel (CILTA-CEL) in lenalidomide-refractory patients with progressive multiple myeloma (MM) after 1–3 prior lines of therapy.
Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAXCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with R/R multiple myeloma are also mentioned.
He concludes by discussing the results from the MAJESTIC trial and the efficacy of cevostamab.
|Updated analysis of IKEMA|
|Latest on CILTA-CEL|
|Progress on bispecific antibodies for treatment of multiple myeloma|
|Other promising immunotherapeutic treatment options|